Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer

Ferdinando Riccardi, Giuseppe Di Lorenzo, Carlo Buonerba, Guglielmo Monaco, Roberto Monaco, Mimma Rizzo, Sarah Scagliarini, Florinda Scognamiglio, Marilena Di Napoli, Giacomo Carteni'

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Defining the optimal treatment for patients with inoperable non small cell lung cancer (NSCLC), presenting with metastatic mediastinal lymph nodes, is challenging. Nevertheless, preoperative chemotherapy or radiotherapy might offer a chance for these patients for radical surgical resection and, possibly, complete recovery.Case Presentation: A 62-year old man with IIIA-N2 inoperable NSCLC was treated with first-line single agent docetaxel. A platinum-based treatment, though considered more active, was ruled out because of renal impairment. The patient tolerated the treatment very well and, although his initial response was not impressive, after 14 cycles he obtained a complete clinical response, which was confirmed pathologically after he underwent surgical lobectomy.Conclusion: In non-operable NSCLC patients not eligible for a platinum-based treatment, single-agent docetaxel can provide complete pathologic responses. Failure to obtain a response after the first few cycles should not automatically discourage to continue treatment.

Original languageEnglish
Article number8
JournalWorld Journal of Surgical Oncology
Volume8
DOIs
Publication statusPublished - Feb 5 2010

ASJC Scopus subject areas

  • Oncology
  • Surgery

Fingerprint Dive into the research topics of 'Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer'. Together they form a unique fingerprint.

Cite this